Would you recommend adjuvant nivolumab for patients with upper tract urothelial cancer?

For any patient with upper tract UC who is eligible for cisplatin, adjuvant cisplatin based chemotherapy would be the preferred standard of care approach. This would be supported by results from the POUT trial where patients treated with cisplatin were deprived significant DFS benefit compared to surveillance. Considering these tumors are enriched in FGFR alterations, enrollment on adjuvant targeted therapy trials would be a preferred approach in cisplatin ineligible patients. Standard of care n...